Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 1/2 1

Status

Completed 6

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 13Head & Neck 12Genitourinary 10Gynecologic 8Endocrine 8Dermatologic 8Thoracic 7Tumor-Agnostic 6CNS 5Sarcoma 4Other solid neoplasm 3NET 3Lymphoid 2Breast 1

Conditions

Neoplasms 5Neoplasm Metastasis 1

Interventions

Paclitaxel 26Carboplatin 25pembrolizumab 22Gemcitabine 22Nivolumab 20Cisplatin 15Bevacizumab 14Docetaxel 13Pemetrexed 12Ipilimumab 12Erlotinib Hydrochloride 12Capecitabine 12Fluorouracil 11Irinotecan 10Afatinib 10eribulin 9BI 6727 9130-nm albumin-bound paclitaxel 9Radiotherapy 8Magnetic Resonance Spectroscopy 8Leucovorin 8Everolimus 8Cyclophosphamide 8Albumin-Bound Paclitaxel 8olaparib 7Oxaliplatin 7lenvatinib 6avelumab 6Trastuzumab 6Cetuximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Has results × lenvatinib × Tumor-Agnostic × Clear all
NCT02640508 2024-05-09

Eribulin and Lenvatinib in Advanced Solid Tumors

The University of Texas Health Science Center at San Antonio

Phase 2 Completed
29 enrolled 13 charts
Tumor-Agnostic

Neoplasms

NCT02501096 2023-07-20

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

Eisai Inc.

Phase 1/2 Completed
357 enrolled 28 charts 1 FDA
Tumor-Agnostic

Neoplasms

NCT01268293 2023-06-22

A Study of E7080 in Subjects With Solid Tumor

Eisai Inc.

Phase 1 Completed
9 enrolled 6 charts
Tumor-Agnostic

Neoplasms

NCT02915783 2023-01-17

A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease

Eisai Inc.

Phase 2 Completed
41 enrolled 11 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT02686164 2019-08-28

Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors

Eisai Inc.

Phase 1 Completed
51 enrolled 11 charts
Tumor-Agnostic

Neoplasms

NCT00280397 2016-10-07

An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors

Eisai Inc.

Phase 1 Completed
27 enrolled 8 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡